Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.52 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009377 | 0.89 | SIRT2 (0.46) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10009245 | 0.88 | SIRT2 (0.65) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10299103 | 0.87 | KMT2A (0.57) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10008113 | 0.85 | SCD (0.54) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10008705 | 0.83 | JAK2 (0.69) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10009298 | 0.81 | LMNA (0.55) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10007869 | 0.81 | NPC1 (0.57) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10008543 | 0.81 | KMT2A (0.65) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10008564 | 0.80 | SIRT2 (0.63) | NPC1RAB9AMEN1MAPTKMT2A | |
| SCHEMBL10007768 | 0.79 | ABL1 (0.61) | NPC1RAB9AMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | claimed |
| WO-2012092471-A2 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | WO | claimed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | claimed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | TUBB1, TUBA1C, TUBB | NPC1 1216/4885RAB9A 1099/4885MEN1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.